Kilitch Drugs (India) Independent Director Venkita Subramanian Rajan resigns
Kilitch Drugs (India) (KILITCH) said Venkita Subramanian Rajan, Independent Director, has resigned. The company is valued at about ₹766 crore.
What happened
In a filing with the BSE on 21 October 2026 at 02:01 PM, Kilitch Drugs (India) (KILITCH) said that Venkita Subramanian Rajan, Independent Director, has resigned.
From the filing: "Venkita Subramanian Rajan has tendered his resignation from the position of Non-executive Independent Director of the Company with immediate effect"
Company snapshot
Kilitch Drugs (India) is a micro-cap company, with a market value of about ₹766 crore.
The stock last traded at ₹219, against a 52-week range of ₹117.3–₹267.9 (18.3% below the high).
Before this filing the shares had moved +16.1% over the month and +22.9% over three months. Average daily turnover over the last 20 sessions was about ₹2.33 crore.
Promoters held 63.77% at the end of Q1 FY27. Foreign institutions owned 0.12% and domestic institutions 0.00%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 43 | 3 | 1.88 |
| Q2 FY26 | 49 | 8.2 | 4.97 |
| Q3 FY26 | 54 | 4.4 | 2.5 |
| Q4 FY26 | 90 | 14.5 | 4.24 |
| Q1 FY27 | 45 | 2.9 | 0.83 |
What history shows
BCEIE has no earlier management change filing from this company on record since May 2026.
Market-wide, 3,974 management change filings with an impact score of 50 or more saw an average next-day move of −0.1%, with 44% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- The appointment of a successor and any change in strategy or guidance.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.